Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

Y K Loke; R Ho; M Smith; O Wong; M Sandhu; W Sage; S Singh

doi:10.1111/jcpt.12080

Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

Y K Loke, R Ho, M Smith, O Wong, M Sandhu, W Sage, S Singh

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

Original language	English
Pages (from-to)	405-415
Number of pages	11
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	38
Issue number	5
DOIs	https://doi.org/10.1111/jcpt.12080
Publication status	Published - Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

5-alpha Reductase Inhibitors
Azasteroids
Cardiovascular Diseases
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Humans
Male
Prostatic Diseases
Randomized Controlled Trials as Topic
Risk

Access to Document

10.1111/jcpt.12080

Cite this

@article{5d61dcdbbde84d0b8df7de9fa4cd2193,

title = "Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride",

abstract = "A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.",

keywords = "5-alpha Reductase Inhibitors, Azasteroids, Cardiovascular Diseases, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Humans, Male, Prostatic Diseases, Randomized Controlled Trials as Topic, Risk",

author = "Loke, {Y K} and R Ho and M Smith and O Wong and M Sandhu and W Sage and S Singh",

note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",

year = "2013",

month = oct,

doi = "10.1111/jcpt.12080",

language = "English",

volume = "38",

pages = "405--415",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "1365-2710",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride

AU - Loke, Y K

AU - Ho, R

AU - Smith, M

AU - Wong, O

AU - Sandhu, M

AU - Sage, W

AU - Singh, S

PY - 2013/10

Y1 - 2013/10

N2 - A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

AB - A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta-analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease.

KW - 5-alpha Reductase Inhibitors

KW - Azasteroids

KW - Cardiovascular Diseases

KW - Double-Blind Method

KW - Drug-Related Side Effects and Adverse Reactions

KW - Humans

KW - Male

KW - Prostatic Diseases

KW - Randomized Controlled Trials as Topic

KW - Risk

U2 - 10.1111/jcpt.12080

DO - 10.1111/jcpt.12080

M3 - Article

C2 - 23815285

SN - 1365-2710

VL - 38

SP - 405

EP - 415

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

IS - 5

ER -